Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
2(20%)
Results Posted
125%(5 trials)
Terminated
2(20%)

Phase Distribution

Ph not_applicable
2
20%
Ph phase_2
5
50%
Ph early_phase_1
2
20%
Ph phase_1
1
10%

Phase Distribution

3

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
2(20.0%)
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
5(50.0%)
N/ANon-phased studies
2(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(4)
Terminated(3)
Other(1)

Detailed Status

Completed4
Terminated2
Withdrawn1
unknown1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (20.0%)
Phase 11 (10.0%)
Phase 25 (50.0%)
N/A2 (20.0%)

Trials by Status

withdrawn110%
unknown110%
active_not_recruiting110%
completed440%
recruiting110%
terminated220%

Recent Activity

2 active trials
Showing 5 of 10
active_not_recruitingphase_2

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

NCT02498613
completedphase_2

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

NCT01507428
completedearly_phase_1

BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy

NCT05250895
recruitingearly_phase_1

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

NCT05996432
completedphase_2

[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer

NCT02695628
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT02498613Phase 2

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Active Not Recruiting
NCT01507428Phase 2

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

Completed
NCT05250895Early Phase 1

BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy

Completed
NCT05996432Early Phase 1

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Recruiting
NCT02695628Phase 2

[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer

Completed
NCT03573986Phase 1

Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment

Terminated
NCT01169350Phase 2

18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma

Terminated
NCT00559377Phase 2

FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer

Completed
NCT01254591Not Applicable

Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer

Unknown
NCT00038038Not Applicable

Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole

Withdrawn

All 10 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
10